Iron deficiency and anaemia in heart failure: Understanding the FAIR-HF trial

European Journal of Heart Failure

Volumn 12, Issue 11, 2010, Pages 1159-1162

  González Costello, José ^a   Comín Colet, Josep ^b  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Anaemia; Chronic heart failure; Iron deficiency; Iron therapy

Indexed keywords

ERYTHROPOIETIN; FERRIC CARBOXYMALTOSE; FERRIC GLUCONATE; IRON; IRON DEXTRAN; IRON SACCHARATE; PLACEBO; PROTON PUMP INHIBITOR; UNCLASSIFIED DRUG;

ANEMIA; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DRUG HYPERSENSITIVITY; ENDURANCE TRAINING; ERYTHROPOIESIS; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HUMAN; HYPOTENSION; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON METABOLISM; MORTALITY; PATHOGENESIS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT RESPONSE;

ANEMIA, IRON-DEFICIENCY; ANIMALS; FERRITINS; HEART FAILURE; HUMANS; INTESTINAL ABSORPTION; IRON; STROKE VOLUME; TRANSFERRIN;

EID: 77958597665     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfq165     Document Type: Review

References (30)

1. De Silva R, Rigby AS, Witte KK, Nikitin NP, Tin L, Goode K, Bhandari S, Clark AL, Cleland JG. Anemia, renal dysfunction, and their interaction in patients with chronic heart failure. Am J Cardiol 2006;98:391-398.
2. Clark AL, Poole-Wilson PA, Coats AJ. Exercise limitation in chronic heart failure: central role of the periphery. J Am Coll Cardiol 1996;28:1092-1102.
3. Westenbrink BD, Visser FW, Voors AA, Smilde TD, Lipsic E, Navis G, Hillege HL, Van Gilst WH, Van Veldhuisen DJ. Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. Eur Heart J 2007;28:166-171.
4. Opasich C, Cazzola M, Scelsi L, De FS, Bosimini E, Lagioia R, Febo O, Ferrari R, Fucili A, Moratti R, Tramarin R, Tavazzi L. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J 2005;26:2232-2237.
5. Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, Schwartz D, Yachnin T, Steinbruch S, Shapira I, Laniado S, Iaina A. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001;37:1775-1780.
6. Comin-Colet J, Ruiz S, Cladellas M, Rizzo M, Torres A, Bruguera J. A pilot evaluation of the long-term effect of combined therapy with intravenous iron sucrose and erythropoietin in elderly patients with advanced chronic heart failure and cardio-renal anemia syndrome: influence on neurohormonal activation and clinical outcomes. J Card Fail 2009;15:727-735.
7. Van Der Meer P, Groenveld HF, Januzzi JL Jr, Van Veldhuisen DJ. Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. Heart 2009;95: 1309-1314.
8. Jin B, Luo X, Lin H, Li J, Shi H. A meta-analysis of erythropoiesis- stimulating agents in anaemic patients with chronic heart failure. Eur J Heart Fail 2010;12:249-253.
9. Van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJ, Wasserman SM, Baker N, Rosser D, Cleland JG, Ponikowski P. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J 2007;28:2208-2216.
10. Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H, Massie BM, Wasserman SM, Trotman ML, Sun Y, Knusel B, Armstrong P. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 2008;117:526-535
11. Desai A, Lewis E, Solomon S, McMurray JJ, Pfeffer M. Impact of erythropoiesis-stimulating agents on morbidity and mortality in patients with heart failure: an updated, post-TREAT meta-analysis. Eur J Heart Fail 2010;12:936-942.
12. McMurray JJ, Anand IS, Diaz R, Maggioni AP, O'Connor C, Pfeffer MA, Polu KR, Solomon SD, Sun Y, Swedberg K, Tendera M, Van Veldhuisen DJ, Wasserman SM, Young JB. Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. Eur J Heart Fail 2009;11:795-801.
13. Bolger AP, Bartlett FR, Penston HS, O'Leary J, Pollock N, Kaprielian R, Chapman CM. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 2006;48:1225-1227.
14. Toblli JE, Lombrana A, Duarte P, Di Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 2007;50:1657-1665.
15. Okonko DO, Grzeslo A, Witkowski T, Mandal AK, Slater RM, Roughton M, Foldes G, Thum T, Majda J, Banasiak W, Missouris CG, Poole-Wilson PA, Anker SD, Ponikowski P. Effect of intravenous iron sucrose on exercise tolerance in anemic and non-anemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol 2008;51:103-112.
16. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart RB, Pocock SJ, Poole-Wilson PA, Ponikowski P. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361: 2436-2448.
17. Usmanov RI, Zueva EB, Silverberg DS, Shaked M. Intravenous iron without ery-thropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. J Nephrol 2008; 21:236-242.
18. Beard JL. Iron biology in immune function, muscle metabolism and neuronal functioning. J Nutr 2001;131(2S-2):568S-579S.
19. Davies KJ, Maguire JJ, Brooks GA, Dallman PR, Packer L. Muscle mitochondrial bioenergetics, oxygen supply, and work capacity during dietary iron deficiency and repletion. Am J Physiol 1982;242:E418-E427.
20. Anker S, von Haehling S. Anaemia in Chronic Heart Failure. 1st ed. Bremen: International Medical Publishers; 2009.
21. Nanas JN, Matsouka C, Karageorgopoulos D, Leonti A, Tsolakis E, Drakos SG, Tsagalou EP, Maroulidis GD, Alexopoulos GP, Kanakakis JE, Anastasiou-Nana MI. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 2006;48:2485-2489.
22. Toblli JESD. Cardio-renal Anaemia Syndrome, 1st ed. Ciudad Autónoma De Buenos Aires: Publicaciones Latinoamericanas SRL; 2008.
23. Handelman GJ, Levin NW. Iron and anemia in human biology: a review of mechanisms. Heart Fail Rev 2008;13:393-404.
24. Andrews NC. Disorders of iron metabolism. N Engl J Med 1999;341:1986-1995.
25. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352: 1011-1023.
26. Van Der Putten K, Jie KE, Van den Broek D, Kraaijenhagen RJ, Laarakkers C, Swinkels DW, Braam B, Gaillard CA. Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/ chronic heart failure patients. Eur J Heart Fail 2010;12:943-950.
27. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, Borodulin-Nadzieja L, Banasiak W, Polonski L, Filippatos G, McMurray JJ, Anker SD, Ponikowski P. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010;15:1872-1880.
28. Van Wyck D, Anderson J, Johnson K. Labile iron in parenteral iron formulations: a quantitative and comparative study. Nephrol Dial Transplant 2004;19:561-565. (Pubitemid 38263113)
29. Silverstein SB, Gilreath JA, Rodgers GM. Intravenous iron therapy: a summary of treatment options and review of guidelines. J Pharm Pract 2008;21:431-443.
30. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Mori C, von Eisenhart RB, Pocock S, Poole-Wilson PA, Ponikowski P. Rationale and design of Ferinject assessment in patients with iron deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. Eur J Heart Fail 2009;11:1084-1091.